You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy

    SBC: GLYTR THERAPEUTICS, INC.            Topic: 102

    AbstractTreatment of non-resectable recurrent/metastatic solid cancers is currently palliative only and there is an urgent unmet need for novel mechanisms of action and additional paradigm shifting therapeutic options. Antigen- targeting cancer immunotherapies such as bi-specific antibodies (eg Bi-specific T cell engager or BiTE’s) provide a unique approach for cancer immunotherapy. However, app ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Developing a novel system combining cognitive assessment with PASCALL FDA-cleared intraoperative anesthesia EEG brain monitor to prevent postoperative neurocognitive disorders in aging patients

    SBC: PASCALL Systems, Incorporated            Topic: NIA

    Each day, more than 100,000 patients undergo general anesthesia in the United States. The current practice of general anesthesia is prone to over-sedating patients, either due to the lack of brain monitoring or using brain monitors with inaccurate indices. Over-sedation (at 28% incidence) contributes to perioperative neurocognitive disorders (PNDs) in elderly population (≥65yrs). The cost of PND ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Chondrofluid for arthroscopic knee cartilage repair

    SBC: CARTILAGE INC            Topic: NIAMS

    PROJECT SUMMARY Minor injuries to articular cartilage can initiate a catabolic cascade, causing small defects to progress into larger, more symptomatic defects. Pain, lesion progression, and accelerated joint deterioration may be avoided with strategies that repair small defects with hyaline-like cartilage. The repair of chondral defects using arthroscopic techniques, performed in a minimally inva ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Advanced optics to unlock large field-of-view multiphoton imaging for neuroscience and beyond

    SBC: PACIFICOPTICA LLC            Topic: 101

    Project summary Currently available optical components limit biomedical imaging. In particular, in neurobiology, standard microscope components limit the field-of-view and speed of imaging of neuronal activity. Through prior work on BRAIN Initiative project, we have developed approaches for new optical components that expand the field-of-view 5 to 50 times over standard microscopes, with no loss i ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Therapy for Hyperphosphatemic Familial Tumoral Calcinosis (hfTC) and Generalized Hyperphosphatemia

    SBC: FGF Therapeutics INC.            Topic: NIAMS

    Abstract Hyperphosphatemic familial tumoral calcinosis (hfTC) is a disease in which patients cannot produce the bioactive form of the hormone Fibroblast growth factor-23 (FGF23), which is secreted by osteocytes to rid the body of phosphate by acting on the kidney. hfTC is characterized by markedly elevated serum phosphate (Pi) which causes large intramuscular calcifications to develop. The calcifi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease

    SBC: TRIANGLE THERAPEUTICS INC.            Topic: 300

    PROJECT SUMMARY Crohn’s disease (CD) is a chronic autoimmune disease in which cells of the immune system attack gut tissue leading to diarrhea, fatigue, pain, and weight loss. CD affects up to one million Americans and is a type of inflammatory bowel disease. CD is driven by CD4 T cells with a significant role for TH1 and TH17 cells and additional involvement of B cells. Current therapies for CD ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Demonstrating miniaturized production of a KOR PET tracer as a proof-of-concept for low-cost distribution of nascent PET neurotracers

    SBC: DropletPharm Inc.            Topic: NIDA

    PROJECT SUMMARY / ABSTRACT Positron-emission tomography (PET) studies play a critical role in many areas of neurological health by enabling quantitative in vivo measurements of specific neuroreceptor systems (e.g. receptor density, drug occupancy, endogenous ligand occupancy) to (i) evaluate fundamental hypotheses about disease or (ii) aid in the development of novel treatments targeting those rec ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Evaluation of recombinant bovine lactoferrin and N-linked glycan effects on infant gut health and immunity

    SBC: TURTLETREE LABS INC.            Topic: NICHD

    Project Summary/Abstract Most infants currently rely on infant formula (IF) to meet their nutritional needs. However, existing infant formula is functionally inferior because it lacks breast milk bioactive proteins that are crucial to infant health and development. Consequently, formula-fed infants have increased risk of morbidity and mortality. Current technology limits the ability to add bioacti ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent

    SBC: PACDNA LLC            Topic: NCI

    Project Summary/Abstract Mutant forms of KRAS are a key driver in human tumors but remain partially refractory to therapeuticintervention. After over three decades of research, only a single inhibitor (sotorasib) targeting a singlemutation (KRASG12C) have reached market. The difficulty for developing small molecule KRAS inhibitorshas heightened the importance of alternative methods targeting the o ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects

    SBC: General Biophysics LLC            Topic: NIA

    PHASE II APPLICATION(STTR Program PAS-22-197) “Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects” ABSTRACTAlzheimer’s disease (AD) is one of the most prevalent neurodegenerative disorders. Emerging evidence shows that homeostatic dysregulation of the brain immune system, especially that orchestrated by microglia, plays a significant role in the onset an ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government